UNIVERSITY of Sydney Faculty of Pharmacy Dr Nial Wheate has published an interesting summary of seven "most notable" new additions to the Pharmaceutical Benefits Scheme.
Wheate highlights the recipients and cost-benefits for each of the products he has chosen: chloramphenicol eye drops (Chlorsig), cystic fibrosis treatment ivacaftor (Kalydeco), immunotherapy blinatumomab (Blincyto), antiemetic fosaprepitant (Emend IV), HIV therapy emtricitabine, multiple sclerosis treatment daclizumab (Zinbryta) and idiopathic pulmonary fibrosis therapy nintedanib (Ofev).
Visit sydney.edu.au for more info.
The above article was sent to subscribers in Pharmacy Daily's issue from 09 May 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 May 17
